Incyte price target raised to $75 from $44 at Jefferies Jefferies raised its price target for Incyte shares to $75 from $44 on expectations the company's IDO inhibitor with ipilimumab for melanoma could "unlock huge value." The firm says it heard positive commentary from four investigators involved in the Phase 2 study and keeps a Buy rating on the stock.
Incyte shares poised to advance further, says Argus Argus believes that Incyte's new products make its revenue outlook "promising." The firm thinks the company's "deep" pipeline could enable it to become a takeover target. Argus keeps a Buy rating on the shares.